Clinical Trials Logo

Seborrhea clinical trials

View clinical trials related to Seborrhea.

Filter by:
  • None
  • Page 1

NCT ID: NCT02494297 Completed - PCOS Clinical Trials

DUS on the Prescribing Indications for CPA/EE in 5 European Countries

Start date: March 6, 2015
Phase:
Study type: Observational

This study was designed to compile the reasons and specific indications for the prescription of Cyproterone Acetate combined with Ethinyl Estradiol by Health Care Providers. The primary objective of the study was to characterize the prescribing behaviors for Cyproterone Acetate combined with Ethinyl Estradiol in 5 European countries (Austria, Czech Republic, France, the Netherlands, and Spain), including: - prescription indications for Cyproterone Acetate combined with Ethinyl Estradiol - use of Cyproterone Acetate combined with Ethinyl Estradiol in accordance with the updated label - concomitant use of Cyproterone Acetate combined with Ethinyl Estradiol and combined hormonal contraceptives - second line treatment with Cyproterone Acetate combined with Ethinyl Estradiol for the indication acne

NCT ID: NCT01254162 Completed - Oily Skin Clinical Trials

Proof of Concept Study of MTC896 Gel to Reduce Sebum Production on the Forehead of Healthy Male Volunteers

Start date: July 2010
Phase: Phase 2
Study type: Interventional

To determine the potential of topically applied 0.75% (w/w) MTC896 Gel to reduce sebum production on the forehead of healthy male volunteers.

NCT ID: NCT01139749 Recruiting - Quality of Life Clinical Trials

Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea

Start date: October 2011
Phase: Phase 4
Study type: Interventional

Oral isotretinoin is the gold standard drug to treat moderate to severe acne. Other indications like seborrhea, seborrheic dermatitis have been suggested. There is risk of reversible mucocutaneous side effects, as well as alterations in lipid profile and transaminases. The major problem is teratogenicity which demands pregnancy control from treatment beginning to one month after treatment end. Seborrhea and seborrheic dermatitis are chronic conditions characterized by oily skin, hair and scalp, erythema, desquamation and negative impact on quality of life. This will be an interventional, therapeutic and quality of life randomized, comparative (parallel groups), blinded evaluation clinical trial, comprising 50 men and women, aged 18 to 40. Treatment with low-dose oral isotretinoin will be compared to topical anti-seborrheic products to evaluate the reduction of sebaceous secretion and colonization of affected areas by yeasts of Malassezia gender. Efficacy will be evaluated by clinical parameters, as well as by sebum secretion measure and application of quality of life questionnaires. Safety will be evaluated by skin hydration measure, side effects report and observation. For subjects using oral isotretinoin blood counting, transaminases, lipid profile and pregnancy test will be requested as selection criteria, on days 30 and 180. Data will be submitted to statistical analysis.